Table 1 Baseline characteristics of study population
From: Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
Characteristics | SCAD + AF (n = 559) | ACS + AF (n = 1491) | P-value |
|---|---|---|---|
Female, n (%) | 256 (45.80) | 672 (45.07) | 0.064 |
Age, (years) | 71.12 ± 0.86 | 72.34 ± 0.76 | 0.841 |
Smoking, n (%) | 172 (30.77) | 450 (30.18) | 0.796 |
Alcohol drinking history, n (%) | 144 (25.76) | 363(24.35) | 0.509 |
ethanol per person per day, (grams) | 5.12 ± 0.75 | 4.86 ± 0.33 | 0.712 |
Heart failure, n (%) | 62 (11.09) | 193 (12.94) | 0.258 |
Arterial hypertension, n (%) | 388 (69.41) | 1068 (71.63) | 0.324 |
Diabetes mellitus, n (%) | 99 (17.71) | 318 (21.33) | 0.070 |
Hypercholesterolemia, n (%) | 171 (30.59) | 519 (34.81) | 0.072 |
Peptic ulcer, n (%) | 20 (3.58) | 43 (2.88) | 0.418 |
Previous stroke, n (%) | 35 (6.26) | 130 (8.72) | 0.069 |
Previous Bleeding, n (%) | 6 (1.07) | 23 (1.54) | 0.423 |
Previous MI, n (%) | 9 (1.61) | 27 (1.81) | 0.758 |
AF type | |||
 Paroxysmal, n (%) | 275 (49.19) | 710 (47.62) | 0.525 |
 Persistent, n (%) | 183 (32.74) | 455 (30.52) | 0.334 |
 Permanent, n (%) | 101 (18.07) | 326 (21.86) | 0.059 |
 CHA2DS2-VASc score | 3.14 ± 1.03 | 3.65 ± 1.22 | 0.422 |
 HAS-BLED score | 2.19 ± 1.38 | 2.12 ± 1.11 | 0.696 |
 PCI, n (%) | 42 (7.51) | 166 (11.13) | 0.016* |
 CABG, n (%) | 3 (0.54) | 18 (1.21) | 0.179 |
 ACEI/ARB, n (%) | 357 (63.86) | 993 (66.60) | 0.245 |
 β-blocker, n (%) | 374 (66.91) | 1041 (69.82) | 0.204 |
 Statins, n (%) | 495 (88.55) | 1288 (86.38) | 0.194 |
 Diuretics, n (%) | 81 (14.49) | 207 (13.88) | 0.725 |
 Digoxin, n (%) | 91 (16.28) | 287 (19.25) | 0.123 |
 CCB, n (%) | 132 (23.61) | 318 (21.33) | 0.266 |
 Proton pump inhibitors, n (%) | 315 (56.35) | 863 (57.88) | 0.533 |
 INR | 2.16 ± 0.42 | 2.27 ± 0.38 | 0.236 |